Cited by 594Immunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

Melief, Cornelis J.M., van der Burg, Sjoerd H.·2008·Nature Reviews Cancer

Abstract

This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses. The most attractive vaccine compounds are synthetic long peptides (SLP) corresponding to the sequence of tumour viral antigens or tumour-associated non-viral antigens. Crucial to induction of therapeutic T-cell immunity is the capacity of SLP to deliver specific cargo to professional antigen-presenting cells (dendritic cells (DC)). Proper DC activation then induces the therapeutic CD4+ and CD8+ T-cell responses that are associated with regression of established (pre)malignant lesions, including those induced by high-risk human papilloma virus.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2373

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Melief, C. J. M., & van der Burg, S. H.
Affiliations
Leiden University Medical Center (NL)
Corresponding author
Melief, Cornelis J.M.
Venue
Nature Reviews Cancer
Published
2008-05
Volume
8
Issue
5
Pages
351-360
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2071244674
Cited by
594
References
1
Citations by year
2026: 23 · 2025: 30 · 2024: 17 · 2023: 32 · 2022: 33 · 2021: 38 · 2020: 37 · 2019: 33 · 2018: 34 · 2017: 22 · 2016: 38 · 2015: 38 · 2014: 45 · 2013: 27 · 2012: 40
FWCI
2.69
Type
journal article
Language
en
Open access
closed
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
cancer immunotherapy, tumor-associated antigens, dendritic cells, antigen presentation, CD4+ T cell responses, CD8+ T cell responses, high-risk HPV, tumor regression
MeSH terms
Animals, Dendritic Cells, Humans, Peptides, Precancerous Conditions, Rabbits, Immunotherapy, Active, Cancer Vaccines, Vaccines, Subunit, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review